SA012 is a First-in-Class (FIC) siRNA product targeting hepatocyte PD-L1 mRNA. Compared to traditional anti-PD-L1 monoclonal antibody treatments for chronic hepatitis B, it has unique advantages: 1) More precise targeting： SA012 acts on hepatocyte PD-L1, restoring the function of exhausted HBV-specific CD8+ T cells, playing an antiviral role; 2) Superior efficacy：Due to its good safety profile, SA012 allows for increased the dosage in clinical use, ensuring sufficient and sustained efficacy; 3) Better safety: The precise hepatic targeting of SA012 can avoid or reduce systemic immune side effects, improving patient compliance.

SA012 is a First-in-Class (FIC) siRNA product targeting hepatocyte PD-L1 mRNA. Compared to traditional anti-PD-L1 monoclonal antibody treatments for chronic hepatitis B, it has unique advantages: 1) More precise targeting： SA012 acts on hepatocyte PD-L1, restoring the function of exhausted HBV-specific CD8+ T cells, playing an antiviral role; 2) Superior efficacy：Due to its good safety profile, SA012 allows for increased the dosage in clinical use, ensuring sufficient and sustained efficacy; 3) Better safety: The precise hepatic targeting of SA012 can avoid or reduce systemic immune side effects, improving patient compliance.

The research results show that SA012 can achieve the best-in-class clearance of HBsAg, with good safety. A single administration of SA012 effectively and sustainably cleared HBsAg and HBV DNA in humanized PD-1/PD-L1 AAV-HBV mice, with 5/7 and 4/7 of the mice reaching the lower limits of detection for HBsAg and HBV DNA, respectively. At the end of the experiment, 5/7 of the mice achieved seroconversion of HBsAg. When SA012 was used in combination with other anti-HBV drugs (such as VIR-2218 or Bepirovirsen),  significant synergistic effects were observed, and no viral rebound was observed throughout the study.

SA012 helps restore HBV-specific acquired immunity, which may be key to preventing viral rebound. Due to its unique mechanism of action, SA012 has great potential in the functional cure of chronic hepatitis B as a monotherapy and in combination with other types of antiviral drugs.

This conference not only highlighted the foresight and professionalism of Siran Bio in the field of chronic hepatitis B drugs, but also further strengthened exchanges and cooperation with industry peers. Siran Bio will continue to be committed to promoting the research,development and application of siRNA technology, and bringing more new treatment options to global chronic hepatitis B patients.

About the European Association for the Study of the Liver (EASL)

Established in 1966, EASL is the largest liver disease research organization in Europe, with over 4,500 members worldwide. Since its inception, EASL has grown from a small organization to an influential international organization. Its mission is to promote research in hepatology; provide state-of-the-art education for physicians and scientists; and raise public awareness of liver diseases and their management, enabling all those involved in liver disease research to reach their full potential and become experts in the field, curing and preventing liver diseases. The annual EASL conference attracts more than 7,000 professionals from over 100 countries worldwide. Participants of the EASL conference include scientific and medical experts in the fields of hepatology, gastroenterology, internal medicine, cell biology, transplant surgery, infectious diseases, microbiology, virology, pharmacology, pathology, radiology, and numerous media representatives.

About Siran Bio

Siran Bio was established in Suzhou Industrial Park in May 2022. It is a biotechnology company focused on the development of innovative siRNA drugs, founded by a top scientific team in the field of nucleic acid therapy and an industrialization expert team.It has received support from the Suzhou Industrial Park's leading and Gusu leading enterprises.

The company has established an industry-leading dual-target nucleic acid drug technology platform and extrahepatic delivery platform with proprietary intellectual property rights, including eSAFE chemical modification technology and STORK intrahepatic and extrahepatic delivery technology platforms. Based on its leading technology platform, the company has rapidly developed a pipeline of small nucleic acid drugs for antiviral, cardiovascular and metabolic diseases, autoimmune, and central nervous system-related diseases.

The company always takes patients as the center, committed to the intelligent manufacturing of the best small nucleic acid drugs, addressing unmet clinical needs, and enhancing human health and happiness.